|
|
|
|
 |
Patent Issued Related to Prometheus Proprietary Test Cbir1 Antigen Test Included in Diagnostic for Inflammatory Bowel Disease |
| Companies mentioned in this article: |
|
Prometheus Laboratories |
|
| 8/21/2008 @ 4:12 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Prometheus Laboratories Inc. announced the issuance of U.S. Patent No. 7,361,733, "Compositions and Methods for the Therapy and Diagnosis of Inflammatory Bowel Disease" which protects a flagellin peptide useful in the detection of antibodies to the flagellin Cbir1, or anti-CBir1, for determining the presence of inflammatory bowel disease (IBD). This proprietary technology is used in the Company's PROMETHEUS IBD Serology 7 test and its recently launched PROMETHEUS IBS Diagnostic test. Prometheus has exclusive rights to this technology under an agreement with Corixa Corporation.
The patent provides a means of detecting the presence and levels of Cbir1 antibodies in a patient sample. Approximately 50% of patients with Crohn's disease have a positive response to anti-CBir1. The presence of anti-CBir1 identifies a subset of patients with Crohn's disease who were not previously detected by other serologic markers. Before the introduction of anti-CBir1, patients who were pANCA positive may have been diagnosed as having ulcerative colitis. However, anti-CBir1 helps physicians to further characterize pANCA-positive patients and distinguish between ulcerative colitis and ulcerative colitis-like Crohn's disease. In addition, anti-CBir1 may be associated with more complicated Crohn's disease and with phenotypes involving small bowel disease, such as fibrostenosis and internal perforating disease.(1)
Prometheus is a leader in providing therapeutics and diagnostics for gastrointestinal diseases and has been at the forefront in offering unique, proprietary testing of blood-based biomarkers with high clinical value. PROMETHEUS IBS Diagnostic is the first blood-based biomarker test to help physicians diagnose irritable bowel syndrome (IBS). PROMETHEUS IBD Serology 7 is the most comprehensive IBD diagnostic testing service available to help physicians detect IBD and differentiate between Crohn's disease and ulcerative colitis.
About IBD and IBS
Crohn's disease and ulcerative colitis are two main types of IBD. The main difference between Crohn's disease and ulcerative colitis is the location and nature of the inflammation. Because the symptoms of Crohn's disease and ulcerative colitis are so similar, it is sometimes difficult to establish a definite diagnosis. However, differentiating between the two diseases is extremely important as treatment may be very different. IBS is a disorder characterized most commonly by cramping, abdominal pain, bloating, constipation and diarrhea. IBS causes substantial discomfort and distress.
About Prometheus
Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. Prometheus focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. Prometheus' strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary, high-value diagnostic testing services. By integrating these therapeutic and diagnostic services, Prometheus addresses the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.
Additional information about Prometheus can be found at www.prometheuslabs.com/.
1 Targan SR, Landers CJ, Yang H, et al. Antibodies to Cbir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2002;123:689-699. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology Posted 9:48 AM PST
Novio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference Posted 7:42 AM PST
Applied Biosystems SOLiD System Named Life Science Innovation of the Year Posted 7:41 AM PST
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference Posted 7:37 AM PST
Aperio Introduces SecondSlide Digital Slide Sharing Network Posted 7:33 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7 in Turkey Posted 7:19 PM PST
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Posted 7:15 PM PST
Biocept Awarded Accreditation by the College of American Pathologists Posted 7:13 PM PST
Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference Posted 7:07 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
Quidel Authorizes Additional $25 Million under Stock Repurchase Program Posted 4:02 PM PST
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Posted 8:54 AM PST
Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products Posted 8:51 AM PST
Nirvanix Plays Supporting Role in Ooyala’s Scalable Video Management Platform Posted 8:49 AM PST
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection Posted 8:47 AM PST
Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference Posted 8:25 AM PST
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia Posted 8:24 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis Posted 4:39 PM PST
Quidel to Present at the 20th Annual Piper Jaffray Healthcare Conference Posted 4:27 PM PST
Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy Posted 4:26 PM PST
Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio Posted 4:25 PM PST
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference Posted 8:49 AM PST
Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense Formulation Posted 8:46 AM PST
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease Posted 8:45 AM PST
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial Posted 8:39 AM PST
PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial Posted 8:36 AM PST
TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Posted 8:35 AM PST
DexCom Receives CE Mark Approval for the SEVEN Continuous Glucose Monitoring System European Association for the Study of Diabetes (EASD) meeting Piper Jaffray 20th Annual Health Care Conference Posted 8:29 AM PST
|
| |
| Monday, November 24, 2008 |
|
|
Visage Imaging and Viatronix Sign Comprehensive Marketing Agreement for Virtual Colonoscopy Product Posted 4:27 PM PST
New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations Posted 4:23 PM PST
Life Technologies to Present at J.P. Morgan Small/Mid Cap Conference Posted 4:22 PM PST
FDA Extends Review of Somaxon Pharmaceuticals’ New Drug Application for Silenor (Doxepin) by up to Three Months Posted 7:44 AM PST
International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing Posted 7:40 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
